Opdivo Adverse Event Report 2018


This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions


Opdivo (nivolumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. Opdivo may be used to treat: advanced skin cancer (melanoma); lung cancer; kidney cancer; classical Hodgkin lymphoma; squamous cell cancer of the head and neck; bladder cancer; liver cancer; or a type of colorectal cancer that laboratory testing proves to have certain specific DNA mutations. Opdivo is often given when the cancer has spread to other parts of the body, or cannot be surgically removed, or has come back after prior treatment. For some types of cancer, Opdivo is given only if your tumor has a specific genetic marker (an abnormal “EGFR” or “ALK” gene).https://www.drugs.com/opdivo.html